Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Joint Association of Complement Component 3 and Cc-Cytokine Ligand2 (Ccl2) or Complement Component 3 and Cfh Polymorphisms in Age-Related Macular Degeneration Publisher Pubmed



Bonyadi M1, 2 ; Jabbarpoor Bonyadi MH3 ; Yaseri M4 ; Mohammadian T1 ; Fotouhi N1 ; Javadzadeh A5 ; Soheilian M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Center of Excellence for Biodiversity, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran
  2. 2. Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  3. 3. Ocular Tissue Engineering Research Center, Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Department of Biostatistics and Epidemiology, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Ophthalmology, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Ophthalmic Genetics Published:2017


Abstract

Background: To determine the joint effect of complement component 3(C3 R102G) with CC-cytokine ligand2 (CCL2-2518) or complement factor H (CFH) Y402H polymorphisms on advanced age-related macular degeneration (AMD). Methods: In this case-control study, 233 patients with advanced AMD and 159 unrelated healthy controls enrolled for evaluation. Selected polymorphisms were determined by polymerase chain reaction and restriction fragment length polymorphism. Results: A combination of AA CCL2 (rs1024611) and GG C3 (R102G) genotypes resulted in a super-additivity of the risks: OR = 10.13, 95% CI 1.04–98.49, p = 0.04, adjusted OR = 7.74, 95% CI 0.71–84.75, p < 0.1, adjusted synergy indices: relative excess risk due to interaction (RERI) = 1.38, the attributable proportion due to interaction (AP) = 24.7% and the synergy index (S) = 1.43. Combination of at-risk genotypes of CFH Y402H and C3 R102G resulted in a strong super-additive risk: adjusted OR = 22.65, 95% CI 2.32–220.91, p = 0.007, adjusted AP = 90.4% and the S = 12.86. Attributable proportion of risk owing to C3-CCL2 and C3-CFH interaction calculated at 25% and 90% for advanced AMD. Conclusion: We have previously shown a strong association of C3 (R102G) and CFH Y402H with AMD whereas no association was found for CCL2-2518. This study enclosed strong synergistic association of risk genotypes of C3 and CFH Y402H with AMD. We also revealed synergistic influence of CCL2-2518 and the at-risk genotype of the C3 in AMD with an estimated AP = 50.9% (adjusted AP = 24.7%). Present findings show that CCL2-2518 polymorphism is not an innocent bystander in AMD susceptibility when combined with the at-risk genotype of C3 (R102G). © 2017 Taylor & Francis.